Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
1st Line Use, Administration Interval Will Be Key Differentiator for Keytruda: MSD Japan Chief
MSD’s anti-PD-1 antibody Keytruda (pembrolizumab) can set itself apart from its archrival Opdivo (nivolumab) with its first-line use and once-every-three-weeks dosing for the treatment of PD-L1-positive unresectable, advanced or relapsed non-small cell lung cancer (NSCLC), the company’s Japan President Jannie…
To read the full story
BUSINESS
- Keytruda Keeps Top Spot in Japan in April-June as Mounjaro Zooms: IQVIA
August 19, 2026
- LEO Pharma Buys Global Rights to Tanabe’s EPP/XLP Drug
August 19, 2026
- J-TEC to Explore Regenerative Medicine Licensing Opportunities in Taiwan
August 19, 2026
- Shionogi to Effectively Scrap Mandatory Retirement from FY2027
August 19, 2026
- Chugai Out-Licenses Anti-Dengue Antibody AID351 to GSK
August 19, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…